Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Zymeworks Inc (ZYME)

38.18   0.4 (1.06%) 06-18 08:42
Open: 37.54 Pre. Close: 37.78
High: 38.61 Low: 37.35
Volume: 396,347 Market Cap: 1,763M
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; collaboration with Applied BioMath, LLC.; and a research collaboration with ImmunoPrecise Antibodies Ltd. for the development of multiple antibody candidates to fight COVID-19. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 38.924 - 39.079 39.079 - 39.212
Low: 37.029 - 37.217 37.217 - 37.379
Close: 37.854 - 38.162 38.162 - 38.427

Technical analysis

as of: 2021-06-17 4:47:44 PM
Overall:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 45.41     One year: 53.04
Support: Support1: 31.25    Support2: 26.53
Resistance: Resistance1: 38.88    Resistance2: 45.41
Pivot: 34.81
Moving Average: MA(5): 37.97     MA(20): 33.36
MA(100): 33.60     MA(250): 38.33
MACD: MACD(12,26): 2.24     Signal(9): 1.66
Stochastic oscillator: %K(14,3): 93.61     %D(3): 95.86
RSI: RSI(14): 73.48
52-week: High: 59.03  Low: 24.82  Change(%): 1.8
Average Vol(K): 3-Month: 42476  10-Days: 45048

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
ZYME has closed below upper band by 22.7%. Bollinger Bands are 26.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 17 Jun 2021
Zymeworks Inc (ZYME) gains 1.0590% for June 17 - Equities.com

Wed, 16 Jun 2021
Zymeworks Inc (ZYME) falls -1.1770% for June 16 - Equities.com

Tue, 15 Jun 2021
Zymeworks Inc (ZYME) gains 0.7380% for June 15 - Equities.com

Mon, 14 Jun 2021
Zymeworks Inc (ZYME) gains 0.5830% for June 14 - Equities.com

Wed, 09 Jun 2021
Zacks: Brokerages Expect Zymeworks Inc. (NYSE:ZYME) to Announce -$1.06 EPS - MarketBeat

Tue, 01 Jun 2021
Zymeworks Inc (ZYME) gains 2.6920% for June 01 - Equities.com

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NYSE
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 46
Shares Float (M) 40
% Held by Insiders 4.16
% Held by Institutions 75.24
Shares Short (K) 1,940
Shares Short P. Month (K) 2,000

Stock Financials

EPS -3.580
EPS Est This Year -2.980
EPS Est Next Year -2.540
Book Value (p.s.) 8.900
Profit Margin
Operating Margin -481.19
Return on Assets (ttm) -25.8
Return on Equity (ttm) -55.1
Qtrly Rev. Growth 735.4
Gross Profit (p.s.) -2.807
Sales Per Share 0.844
EBITDA (p.s.) -3.988
Qtrly Earnings Growth
Operating Cash Flow (M) -151
Levered Free Cash Flow (M) -98

Stock Valuations

PE Ratio -10.66
PEG Ratio
Price to Book value 4.29
Price to Sales 45.25
Price to Cash Flow -11.64

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.